Gilead Sciences Executive and Leadership Team

Amy Klug, the Vice President, Chief of Staff, Corporate Strategy and Projects, Chief Executive Officer Office at Gilead Sciences, executes the strategic vision defined by the executive leadership team. Overseeing high-priority corporate projects, the Vice President, Chief of Staff, Corporate Strategy and Projects, Chief Executive Officer Office ensures that cross-functional teams remain focused on core business objectives, such as the expansion of oncology and viral hepatitis portfolios. This role involves managing the flow of information to the Chief Executive Officer and facilitating decision-making processes across the organization. By coordinating complex strategic initiatives, Amy Klug drives operational efficiency and ensures that the company remains agile in the face of evolving market demands. The Vice President, Chief of Staff, Corporate Strategy and Projects, Chief Executive Officer Office also monitors the progress of key research collaborations, ensuring that strategic partnerships contribute effectively to the long-term growth and innovation goals of the company.

Andrew Dickinson, the Chief Financial Officer at Gilead Sciences, directs all global financial operations and capital allocation strategies. Managing the fiscal health of the organization, the Chief Financial Officer oversees long-term investment planning, investor relations, and financial reporting standards. This leadership role involves balancing the high costs of biopharmaceutical research with the need for sustainable revenue growth across HIV, viral hepatitis, and oncology portfolios. By optimizing capital structure and resource distribution, Andrew Dickinson directly impacts the ability of the company to pursue strategic collaborations and license agreements. Furthermore, the Chief Financial Officer ensures that financial performance aligns with the broader mission of delivering life-saving medicines to patients in the United States, Europe, and international markets. Dickinson maintains rigorous oversight of budgetary controls to support the ongoing development of complex therapeutic pipelines.

Erik Schroeppel, the Chief Marketing Officer, Supply Chain & Manager at Gilead Sciences, architects the commercial distribution strategies for critical pharmaceutical products. Overseeing the complex logistics network, the Chief Marketing Officer, Supply Chain & Manager ensures that life-saving treatments like Biktarvy and Veklury reach patients across diverse global regions efficiently. This role involves managing the intricate balance between market demand forecasting and inventory production cycles to prevent supply disruptions. By integrating marketing insights with supply chain logistics, Erik Schroeppel drives the availability of essential medicines in both domestic and international territories. The Chief Marketing Officer, Supply Chain & Manager coordinates with manufacturing teams to maintain high quality standards while scaling operations to meet evolving healthcare needs. Ultimately, Schroeppel secures the reliable delivery of therapeutic assets, supporting the company's market position in the competitive biopharmaceutical landscape.

Deborah Son, the Chief Marketing Officer, Supply Chain at Gilead Sciences, manages the strategic procurement and operational flow of raw materials required for pharmaceutical manufacturing. Focusing on the upstream supply chain, the Chief Marketing Officer, Supply Chain optimizes vendor relationships and material sourcing to ensure the consistent production of oncology and viral hepatitis treatments. This leadership function involves mitigating risks within the global supply network to maintain uninterrupted manufacturing capacity. By aligning procurement strategies with commercial objectives, Deborah Son supports the rapid deployment of new therapies into the marketplace. The Chief Marketing Officer, Supply Chain collaborates with internal research and development teams to anticipate future material requirements for emerging drug candidates. Through meticulous oversight of the supply chain infrastructure, Son ensures that the company maintains a robust and resilient foundation for its extensive portfolio of life-saving medical products.

Naomi Bautista, the Gain Chief of Staff (Gilead Asian Interest Network) at Gilead Sciences, drives internal initiatives that foster diversity, equity, and inclusion within the corporate culture. Overseeing the strategic alignment of the Gilead Asian Interest Network, the Gain Chief of Staff (Gilead Asian Interest Network) coordinates programs that support professional development and cultural awareness across the global workforce. This leadership role involves facilitating communication between employee resource groups and executive management to ensure diverse perspectives influence corporate decision-making. By championing inclusive practices, Naomi Bautista strengthens the organizational fabric, which directly supports the company's ability to attract and retain top-tier scientific and operational talent. The Gain Chief of Staff (Gilead Asian Interest Network) also manages internal projects that promote a collaborative environment, ensuring that the company's internal culture reflects the global patient populations served by its innovative pharmaceutical products.

Courtney Desmond, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer at Gilead Sciences, manages the operational framework for corporate governance and regulatory adherence. Overseeing the integration of ethical standards into daily business practices, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer ensures that all commercial and research activities comply with international healthcare regulations. This leadership role involves coordinating with legal and compliance teams to mitigate risks associated with global pharmaceutical operations. By streamlining communication between the compliance office and other departments, Courtney Desmond supports a culture of integrity that protects the company's reputation and operational license. The Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer also facilitates the implementation of internal policies that govern interactions with healthcare providers and research partners, ensuring that all activities align with the highest standards of professional conduct.

Susanna Stinson, the Director, Research Chief of Staff and Strategic Projects at Gilead Sciences, directs the operational planning for the research and development division. Overseeing the allocation of resources for drug discovery, the Director, Research Chief of Staff and Strategic Projects ensures that scientific teams have the necessary support to advance novel therapies from the laboratory to clinical trials. This role involves managing the project portfolio for HIV, oncology, and fungal infection research, ensuring that milestones are met within established timelines. By coordinating between research scientists and corporate leadership, Susanna Stinson drives the strategic focus of the R&D pipeline. The Director, Research Chief of Staff and Strategic Projects also manages the integration of new research collaborations and license agreements, ensuring that external innovations are effectively incorporated into the company's internal development efforts to address unmet medical needs globally.

Christopher Iwata, the Chief of Staff To the Executive Vice President of Human Resources at Gilead Sciences, manages the strategic initiatives related to talent acquisition, organizational development, and workforce planning. Overseeing the implementation of human capital strategies, the Chief of Staff To the Executive Vice President of Human Resources ensures that the company maintains a high-performing workforce capable of supporting complex biopharmaceutical operations. This role involves coordinating with leadership to align talent management with the company's long-term growth objectives in the United States and international markets. By facilitating communication and project execution within the HR division, Christopher Iwata drives the development of programs that enhance employee engagement and professional growth. The Chief of Staff To the Executive Vice President of Human Resources also monitors organizational health metrics, ensuring that the company's human resources infrastructure remains robust enough to support the ongoing innovation and commercialization of life-saving medical products.